(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.82%) $83.16
(-1.16%) $1.619
(-0.42%) $2 337.30
(0.98%) $27.52
(0.64%) $928.00
(-0.17%) $0.933
(-0.14%) $11.01
(-0.24%) $0.798
(0.00%) $92.17
Live Chart Being Loaded With Signals
Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of chemotherapy resistance. Its lead product candidate includes the SCO-101, an oral compound that is in clinical Phase Ib and Phase II studies in cancer patients...
Stats | |
---|---|
今日成交量 | 37 251.00 |
平均成交量 | 175 226 |
市值 | 61.06M |
EPS | SEK0 ( 2024-02-27 ) |
下一个收益日期 | ( SEK0 ) 2024-05-29 |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | -1.000 |
ATR14 | SEK0.0480 (3.20%) |
音量 相关性
Scandion Oncology A/S 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Scandion Oncology A/S 相关性 - 货币/商品
Scandion Oncology A/S 财务报表
Annual | 2023 |
营收: | SEK0 |
毛利润: | SEK0 (0.00 %) |
EPS: | SEK-0.960 |
FY | 2023 |
营收: | SEK0 |
毛利润: | SEK0 (0.00 %) |
EPS: | SEK-0.960 |
FY | 2022 |
营收: | SEK0 |
毛利润: | SEK0 (0.00 %) |
EPS: | SEK-1.790 |
FY | 2021 |
营收: | SEK0.00 |
毛利润: | SEK0.00 (0.00 %) |
EPS: | SEK-1.610 |
Financial Reports:
No articles found.
Scandion Oncology A/S
Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of chemotherapy resistance. Its lead product candidate includes the SCO-101, an oral compound that is in clinical Phase Ib and Phase II studies in cancer patients. The company's other product candidate is SCO-201, which is in preclinical trial for the treatment of solid tumors. Scandion Oncology A/S was founded in 2017 and is headquartered in Copenhagen, Denmark.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。